Showing 2,041 - 2,060 results of 2,092 for search '"chemotherapy"', query time: 0.08s Refine Results
  1. 2041

    Beyond first-line therapy: efficacy and safety outcomes of continuing immunotherapy in extensive stage small cell lung cancer after PD-L1 inhibitor progression by Jianfeng Peng, Xueying Zhai, Xiaomei Liu, Zhaoqin Huang, Yimeng Wang, Peizhu Wu, Ran Gao, Xiangjiao Meng

    Published 2025-02-01
    “…Methods: A retrospective analysis was conducted on patients with ES-SCLC who experienced disease progression after receiving programmed cell death ligand 1 (PD-L1) inhibitors combined with standard chemotherapy as first-line treatment at three sites in China. …”
    Get full text
    Article
  2. 2042

    Collagen turnover biomarkers to predict outcome of patients with biliary cancer by Leonard Kaps, Muhammed A. Genc, Markus Moehler, Stephan Grabbe, Jörn M. Schattenberg, Detlef Schuppan, Rasmus Sund Pedersen, Morten A. Karsdal, Philipp Mildenberger, Annett Maderer, Nicholas Willumsen

    Published 2025-02-01
    “…Methods We measured the seven biomarkers of collagen turnover in sera of 72 patients with BTC at baseline and after first and second chemotherapy cycle (CTX). Markers were also assessed in sera of 50 healthy controls and compared to levels of patients at baseline. …”
    Get full text
    Article
  3. 2043

    Whole lung radiomic features are associated with overall survival in patients with locally advanced non-small cell lung cancer treated with definitive radiotherapy by Meng Yan, Zhen Zhang, Jia Tian, Jiaqi Yu, Andre Dekker, Dirk de Ruysscher, Leonard Wee, Lujun Zhao

    Published 2025-01-01
    “…Methods A total of 661 patients with LA-NSCLC treated with definitive radiotherapy in combination with chemotherapy were enrolled in this study, with 292 patients in the training set, 57 patients from the same hospital from January to December 2017 as an independent test set (test-set-1), 83 patients from a multi-institutional prospective clinical trial data set (RTOG0617) as test-set-2, and 229 patients from a Dutch radiotherapy center as test-set-3. …”
    Get full text
    Article
  4. 2044

    L-glutaminase synthesis by Klebsiella pneumoniae (AS KP 23) isolated from clinical strain, and its efficacy against human hepatocellular and breast cancer cell lines by Lina J. Abdel-Hafez, Eman Y. T. Elariny, Asmaa E. Ibrahim, Mahmoud E. F. Abdel-Haliem

    Published 2025-02-01
    “…L-glutaminase has been cited as the most potent molecule that inhibits the proliferation of cancer cells, which significantly raises the possible applicability of cancer therapy and the possibility of its application as an alternative drug to chemotherapy. The first investigation into the antitumor property of L-glutaminase revealed its inhibitory effect on the growth of Gardner lymphosarcoma (6C3HED) and L-1210 leukemia cells. …”
    Get full text
    Article
  5. 2045

    Platinum drugs upregulate CXCR4 and PD‐L1 expression via ROS‐dependent pathways, with implications for novel combined treatment in gastric cancer by Xiaoyu Kang, Lin Zhang, Shushang Liu, Fei Wang, Haiming Liu, Fenli Zhou, Fei Wu, Haohao Zhang, Daiming Fan, Yongzhan Nie, Zhangqian Chen

    Published 2025-01-01
    “…Similarly, GC xenografts treated with platinum‐based chemotherapy exhibited increased CXCR4 and PD‐L1 expression levels compared to saline‐treated controls (p < 0.05). …”
    Get full text
    Article
  6. 2046

    Survival after Locoregional Treatments for Hepatocellular Carcinoma: A Cohort Study in Real-World Patients by Simona Signoriello, Annalisa Annunziata, Nicola Lama, Giuseppe Signoriello, Paolo Chiodini, Ilario De Sio, Bruno Daniele, Giovanni G. Di Costanzo, Fulvio Calise, Graziano Olivieri, Vincenzo Castaldo, Rosario Lanzetta, Guido Piai, Giampiero Marone, Mario Visconti, Mario Fusco, Massimo Di Maio, Francesco Perrone, Ciro Gallo, Giovanni B. Gaeta

    Published 2012-01-01
    “…We investigated, in a retrospective cohort study, whether surgical resection, radiofrequency ablation (RFA), percutaneous ethanol injection (PEI), and transarterial embolization with (TACE) or without (TAE) chemotherapy resulted in different survival in clinical practice. …”
    Get full text
    Article
  7. 2047

    Idiopathic multicentric Castleman disease in children: a single-center retrospective analysis by Junye Du, Jiafeng Yao, Honghao Ma, Li Li, Ang Wei, Liping Zhang, Dong Wang, Zhigang Li, Rui Zhang, Tianyou Wang

    Published 2025-01-01
    “…Results A total of 9 children were enrolled, with a median age of onset of median 11 (2–15) years, 6 males and 3 female. 3 cases were pathologically typed as plasma cell type, 1 case was mixed type, and the remaining 5 cases were hyaline vascular type. 9 children received different regimens of chemotherapy. The median follow-up time was 26 (13, 58) months, with no deaths, 7/9 cases showing improvement, 1/9 cases showing stable condition, and 1/9 cases showing active condition. …”
    Get full text
    Article
  8. 2048

    Establishment of a Novel Model for Anticancer Drug Resistance in Three-Dimensional Primary Culture of Tumor Microenvironment by Tatsuya Usui, Masashi Sakurai, Shuhei Enjoji, Hideyoshi Kawasaki, Koji Umata, Takashi Ohama, Nobuyuki Fujiwara, Ryotaro Yabe, Shunya Tsuji, Hideyuki Yamawaki, Shoichi Hazama, Hiroko Takenouchi, Masao Nakajima, Ryouichi Tsunedomi, Nobuaki Suzuki, Hiroaki Nagano, Koichi Sato

    Published 2016-01-01
    “…These findings indicate that ALI organoid culture from colorectal cancer patients may become a novel model that is useful for examining resistance to chemotherapy in tumor microenvironment.…”
    Get full text
    Article
  9. 2049

    Revealing the heterogeneity of treatment resistance in less‐defined subtype diffuse large B cell lymphoma patients by integrating programmed cell death patterns and liquid biopsy by Wei Hua, Jie Liu, Yue Li, Hua Yin, Hao‐Rui Shen, Jia‐Zhu Wu, Yi‐Lin Kong, Bi‐Hui Pan, Jun‐Heng Liang, Li Wang, Jian‐Yong Li, Rui Gao, Jin‐Hua Liang, Wei Xu

    Published 2025-01-01
    “…Furthermore, our research indicated that patients with elevated PCDI scores could potentially show resistance to conventional chemotherapy treatments, yet they might derive an advantage from alternative inhibitors targeting specific signalling pathways. …”
    Get full text
    Article
  10. 2050

    Recent advances in systemic therapy for advanced biliary tract cancer: A systematic review and meta-analysis using reconstructed RCT survival data by Zhihao Li, Daniel Aliseda, Owen Jones, Luckshi Rajendran, Christian Magyar, Robert Grant, Grainne M. O’Kane, Anna Saborowski, Gonzalo Sapisochin, Arndt Vogel

    Published 2025-03-01
    “…Following positive results from the TOPAZ-01 and KEYNOTE-966 trials, immune checkpoint inhibitors (ICIs) combined with chemotherapy are now the standard of care. We aim to compare the efficacy of first-line therapies for advanced BTCs. …”
    Get full text
    Article
  11. 2051

    The role of smell in medical and psychological disorders: An interdisciplinary approach by Giuseppe Riva

    Published 2019-11-01
    “…Furthermore, the psychophysical evaluation of olfactory impairments associated with some treatments, such as radiotherapy and chemotherapy, and with several types of rhinitis could help address patients’ complaints, and increase the patient’s quality of life [10, 11]. …”
    Article
  12. 2052

    Gut microbiota derived DCA enhances FOLFOX efficacy via Ugt1a6b mediated enterohepatic circulation in colon cancer by Qian Fang, Xiaoying Hou, Limei Fan, Yufei Deng, Xiaoxuan Li, Hongyun Zhang, Haiping Wang, Zhengqi Fu, Binlian Sun, Xiji Shu, Hongzhi Du, Yuchen Liu

    Published 2025-03-01
    “…FOLFOX (5-Fluorouracil, Calcium Folinate combined with Oxaliplatin) is a preferred chemotherapy regimen for colon cancer, but its limited efficacy remains a major challenge, significantly impairs patient outcomes. …”
    Get full text
    Article
  13. 2053

    Phase I study of efineptakin alfa (NT-I7) for the treatment of Kaposi sarcoma by Leonard D’Amico, Martin Cheever, Steven P Fling, Anna Wright, Kathryn Lurain, Ramya Ramaswami, Irene Ekwede, Thomas S Uldrick, Robert Yarchoan, Judith C Kaiser, Angela Shaulov Kask, Manoj P Menon, Paul Couey, Eli Burnham, Allysson Angeldekao, Byung Ha Lee, Li-Lian Kwok, Chia-Ching Jackie Wang

    Published 2025-02-01
    “…Background CD4+ T-cell lymphocytopenia and immune dysfunction are factors that drive the onset and persistence of Kaposi sarcoma (KS) in people with (PWH) and without HIV. Standard chemotherapy agents for KS can contribute to increasing CD4+ T cell lymphocytopenia. …”
    Get full text
    Article
  14. 2054

    Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer by Lei Wang, Yafei You, Wenzhuo He, Yu Hou, Lan Li, Li Wang, Chang Jiang, Jiahong Yi, Yaoxiong Xia, Liangping Xia

    Published 2025-01-01
    “…Besides, patients previously treated with platinum-based chemotherapy (PBC) also revealed worse median PFS comparing with those without previous PBC (8.0 vs. 18.6 months, P = 0.023). …”
    Get full text
    Article
  15. 2055

    PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesothelioma by Solange Peters, Urania Dafni, Panagiota Zygoura, Sanjay Popat, Mary O'Brien, Rolf A Stahel, Alessandra Curioni-Fontecedro, Georges Coukos, Amy Roy, Riyaz Shah, Krisztian Homicsko, James Spicer, Stephen P Finn, David Gilligan, Maxim Norkin, Stephanie Tissot, Nicholas Shakarishvili, Anthony Pope, Patricia Fisher, Sylvie Rusakiewicz, Ekaterina Fortis, Nesa Marti, Roswitha Kammler

    Published 2023-10-01
    “…We aimed to identify novel markers in malignant pleural mesothelioma to select patients better.Methods We performed a multiplex-immune histochemistry analysis of tumor samples from the phase III PROMISE-meso study, which randomized 144 pretreated patients to receive either pembrolizumab or standard second-line chemotherapy. Our panel focused on CD8+T cell, CD68+macrophages, and the expression of PD-1 and PD-L1 on these and cancer cells. …”
    Get full text
    Article
  16. 2056

    A multicenter retrospective study of early cardiac toxicity in operable breast cancer patients receiving concurrent dual or mono anti-HER2 therapy with postoperative radiation ther... by Jing Yang, Meng-Yun Zhou, Bo Yu, Qing Lin, Yuan Yao, Hua-Ling Wu, Qi-Wei Zhu, Ming Ye, Hua-Ying Xie, Jian-Wei Wu, Gang Cai, Rong Cai, Wei-Xiang Qi, Jia-Yi Chen, Lu Cao

    Published 2025-02-01
    “…Among right-sided patients or patients receiving anthracycline-based chemotherapy, the dual-targeted cohort had a higher risk of developing ECG abnormalities compared to the trastuzumab-only cohort. …”
    Get full text
    Article
  17. 2057

    Prevalence, Risk Factors, and Coinfection of Urogenital Schistosomiasis and Soil-Transmitted Helminthiasis among Primary School Children in Biase, Southern Nigeria by Kenneth Nnamdi Opara, Eteye Udobong Wilson, Clement Ameh Yaro, Luay Alkazmi, Nsima Ibanga Udoidung, Friday Maduka Chikezie, Bassey Eyibio Bassey, Gaber El-Saber Batiha

    Published 2021-01-01
    “…Although the degree of infection is quite low or moderate, there is a need to intensify and sustain control measures such as provision of sustainable clean water supply, health education intervention, and chemotherapy.…”
    Get full text
    Article
  18. 2058
  19. 2059
  20. 2060

    Recurrent adenoid cystic carcinoma of the left upper palate accompanied by massive maxillary hemorrhage: a case report and literature review by ZHANG Wangru, CHEN Yuanyuan, LI Zhiping, MENG Jian

    Published 2025-01-01
    “…In complex cases involving positive margins, recurrence, and metastasis, the MDT model employed interdisciplinary collaboration to devise a comprehensive treatment plan that may have included re-operation, radiotherapy, and chemotherapy, with the aim of minimizing the risk of ACC recurrence and controlling distant metastasis. …”
    Get full text
    Article